Miniature telescope in dry AMD: Surgical implantation improves vision for patients with late-stage AMD
Albert J. Augustin, MD, presented a talk entitled, “First Results of the Miniature Telescope in Dry AMD” in Fort Lauderdale, Florida. The Galilean telescope device offers visual improvements for patients with late-stage AMD.
Evaluating effect of central subfield thickness, volatility on visual acuity in clinical trials for nAMD
Justis P. Ehlers, MD, dissects the revelations from the data in the Phase 3 Hawk clinical trial regarding the impact of central subfield thickness, volatility and the overall impact on visual acuity.
Copernicus and Galileo trials: Effect of time since diagnosis on BCVA outcomes in CRVO
Dilsher Dhoot, MD, discusses the post hoc analysis of the Copernicus and Galileo trials, which investigated if a delay in treatment would affect visual acuity gains or change in anatomy.
Phase 3 Archway end-of-trial results: Port Delivery System is noninferior to monthly ranibizumab
Aleksandra Rachitskaya, MD, discussed the Phase 3 Archway end-of-trial results for the investigation of the Port Delivery System with ranibizumab in neovascular AMD.
Expanding the therapeutic arsenal for noninfectious uveitis, uveitic macular edema
Steven Yeh, MD, provides a brief overview of available therapies for noninfectious uveitis and uveitis macular edema.
Phase 3 investigation of OPT-302 combination therapy assess superiority in mean BCVA over anti-VEGF-A monotherapy
David Boyer, MD, discusses the Phase 3 investigation for OPT-302 combination therapy for wet AMD.
Hypersonic vitrectomy: Novel technology for vitreous removal
Though the speed of traditional guillotine cutters has increased significantly in recent years, there are certain limitations. With the advent of hypersonic vitrectomy, Sunir J. Garg, MD, FACS, explains how retinal surgeons can remove the vitreous gel with more efficiency.
Carl Regillo, MD, outlines latest results of KSI-301 clinical trial
While the DAZZLE trial failed to meet its primary endpoint, KSI-301 demonstrated good initial visual gains and anatomic effects as well as positive durability.
YOSEMITE and RHINE trials yield durability, retinal fluid reduction, DME resolution with faricimab
In the study, the faricimab molecule, which is a combined anti-Ang2 and anti-VEGF, performed better than the aflibercept drug in many different ways. Rishi P. Singh, MD, FASRS, summarizes some of these key findings.
Managing the treatment of patients with endophthalmitis
Finding uveitis in the clinic: Imaging, tests to catch signs and symptoms
Yasha S. Modi, MD, discusses his best tips and tricks for finding and diagnosing infectious uveitis.
Investigating the efficacy of targeting the Ang/Tie2 pathway with faricimab
Professor Anat Loewenstein, MD, discusses data regarding the efficacy of faricimab at targeting both the VEGF and Ang2 pathways in patients with neovascular AMD and diabetic macular edema.
EYP-1901 introduces treat-to-maintain paradigm for anti-VEGF therapy
EyePoint Pharmaceuticals hopes to usher in a new paradigm of retinal eye disease treatments with their candidate EYP-1901.
Tissue preservation should be considered as endpoint for geographic atrophy therapies
As novel therapies in the pipeline are aiming to decrease the rate of GA expansion—the endpoint Karl Csaky, MD and Fredrick Ferris III, MD, identified in 2007—Dr. Csaky reinforces on the importance of preserving the central retinal tissue.
Poll results: Are you attending Retina World Congress 2022?
Results from our recent poll regarding Retina World Congress 2022 attendance indicate that while many retina specialists will attend the Congress, the majority will not be in Fort Lauderdale, Florida.
POLL: Are you attending Retina World Congress 2022?
A poll for retina specialists regarding their attendance at the 2022 Retina World Congress in Fort Lauderdale, Florida. This poll is now closed.
2 Commerce Drive Cranbury, NJ 08512